Avacta Group has been granted a patent for a polypeptide with specific mutations and high sequence identity to a reference sequence. The polypeptide includes heterologous peptides and a scaffold protein with a N32G mutation. This innovation opens new possibilities in protein engineering. GlobalData’s report on Avacta Group gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Avacta Group, Laboratory automation robots was a key innovation area identified from patents. Avacta Group's grant share as of May 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
Polypeptide with n32g mutation and heterologous peptides
A recently granted patent (Publication Number: US11952415B2) discloses a novel polypeptide comprising a scaffold protein sequence with specific mutations and identity criteria. The polypeptide includes a N32G mutation relative to a defined amino acid sequence and has at least 90% identity to the same sequence. Additionally, the polypeptide incorporates two heterologous peptides inserted within the scaffold protein sequence, with specific insertion positions and length requirements. The patent also covers variations of the polypeptide with different mutations and identity percentages, further expanding the scope of the invention.
Moreover, the patent extends to applications involving host cells containing the described polypeptide and fusion proteins incorporating the polypeptide along with additional amino acid sequences like signal sequences, affinity tags, and transmembrane domains. The fusion proteins may also include half-life extension polypeptides, enhancing their stability and functionality. The detailed claims outline the specific mutations, insertion positions, and length constraints for the heterologous peptides, providing a comprehensive framework for the development and utilization of these novel polypeptides and fusion proteins in various biotechnological and therapeutic applications.
To know more about GlobalData’s detailed insights on Avacta Group, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
